May 06, 2010 at 09:00 AM EDT
Antares Pharma to Host First Quarter 2010 Earnings Call

Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it will release its first quarter 2010 financial results after the market closes on Thursday, May 13, 2010, and host a conference call shortly thereafter at 4:30 p.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, Executive Vice President, Chief Financial Officer and President of the Parenteral Products Division, will host the call.

Interested parties may participate in the conference call by dialing 877-941-0843 (US) or 480-629-9644 (international), 5-10 minutes prior to the start of the call. A replay of the conference call will be available approximately 2 hours after the call’s conclusion through 12:00 p.m. ET (Eastern Time) on May 27, 2010 by dialing 800-406-7325 (US) or 303-590-3030 (international), and entering the reservation # 4293944. An audio web cast and archive of the conference call will also be available under the investor relations section of the Antares Web site at www.antarespharma.com.

About Antares Pharma

Antares Pharma focuses on self-injection delivery technologies and topical gel-based pharmaceutical products. The Company's subcutaneous and intramuscular injection technology platforms include VIBEXTM disposable pressure-assisted auto injectors, ValeoTM/VisionTM reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd that includes Tev-Tropin® human growth hormone and a partnership with Ferring Pharmaceuticals. In the gel-based area, the Company's lead product candidate, Anturol® an oxybutynin ATDTM gel for the treatment of OAB (overactive bladder), is currently under evaluation in a pivotal Phase 3 trial. Antares also has a partnership with BioSante that includes LibiGel® (transdermal testosterone gel) in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development and product commercialization activities in Minneapolis, Minnesota and Muttenz, Switzerland.

Contacts:

Antares Pharma, Inc.
Robert F. Apple
Chief Financial Officer
(609) 359-3020
or
Investors:
Westwicke Partners, LLC
John Woolford
(443) 213-0506
john.woolford@westwicke.com
or
Media:
Tiberend Strategic Advisors, Inc.
Tamara Bright
(212) 827-0020
tbright@tiberendstrategicadvisors.com
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here